QualityStocksNewsBreaks Archives - Page 2 of 1502

WednesdayFeb 18, 2026 9:10 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Raises Preliminary FY 2025 Revenue to $38-$40 Million, Reaffirms $200 Million FY 2026 Target

Datavault AI (NASDAQ: DVLT) updated its preliminary, unaudited fiscal 2025 revenue estimate to $38 million to $40 million, exceeding its prior $30 million estimate by up to 33%, with midpoint growth of approximately 1,300% year over year, driven by customer tech-licensing fees and tokenization and monetization services from its Data Science Group. The company also reaffirmed its anticipated fiscal 2026 revenue target of $200 million, representing projected year-over-year growth of 400% to 426%, and said it plans to file its audited 2025 financial results with the SEC next month. To view the full press release, visit https://ibn.fm/Z5sSf About Datavault AI…

TuesdayFeb 17, 2026 3:33 pm

QualityStocksNewsBreaks – Globavend Holdings Limited (NASDAQ: GVH) Reports 42.5% Revenue Growth for Fiscal 2025

Globavend Holdings (NASDAQ: GVH) reported financial results for the year ended Sept. 30, 2025, with revenue rising 42.5% year over year to $23.6 million. The company said it handled an average of 10,394 packages per day, up 69.4% from the prior year, while average daily revenue per freight weight increased 12.7%. Net income totaled $0.68 million. During the year, Globavend established a subsidiary in China and built out corporate infrastructure to support expansion, as management cited capital markets support and a growing pipeline positioning the company for continued revenue growth into 2026 and beyond. To view the full press release, visit https://ibn.fm/MUSnQ About Globavend Holdings Limited Globavend Holdings Limited,…

TuesdayFeb 17, 2026 2:41 pm

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and…

TuesdayFeb 17, 2026 2:18 pm

QualityStocksNewsBreaks – Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) Options Waterslide Uranium and Rare Earth Project in Ontario

This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising. Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) announced it has entered into an option agreement with Gallik Explorations Inc. to earn up to a 100% interest in the 2,300-hectare Waterslide Property located approximately 20 km southeast of Bancroft, Ontario, subject to Canadian Securities Exchange approval. The property hosts seven documented uranium, thorium, fluorite and rare earth occurrences within the Central Gneiss Belt of the Grenville Province, and Canamera may secure full ownership through four staged cash and share payments totaling $200,000 over three years, after which the project will carry a 2% net smelter…

TuesdayFeb 17, 2026 1:53 pm

QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Appoints Galen Carson to Advisory Board

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold (CSE: ESAU) (OTCQB: ESAUF) announced the appointment of Galen Carson, founder and principal of Caram Media Inc., to its advisory board, formalizing a strategic relationship that began in October 2024 and supported the company’s capital markets strategy and investor positioning during a period of transformation. Since that time, ESGold has raised more than C$20 million to advance its fully permitted Montauban Gold-Silver Project toward production, expanded its shareholder base and increased market capitalization, as the company prepares for a fully funded path to initial gold and silver production in 2026 while continuing exploration…

TuesdayFeb 17, 2026 1:17 pm

QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Submits Final Phase 1 Report Under US Department of War OTA

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) announced submission of its final reporting under Phase 1 of its Other Transaction Agreement with the US Department of War to the US Army Contracting Command – Orlando, including a Final Demonstration Report and Techno-Economic Analysis for work completed at its RapidSX(TM) Commercialization and Demonstration Facility. The report detailed approximately 6,000 hours of simulated commercial operation and more than 10,000 recovery and purity comparison points, demonstrating that Ucore’s proprietary RapidSX(TM) platform efficiently executed solvent extraction chemistry and produced thousands of liters of rare earth chloride products, supporting its scalability and capital efficiency compared with conventional solvent extraction methods. To view…

TuesdayFeb 17, 2026 10:15 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers. To view the full press release, visit https://ibn.fm/lcSDZ About…

TuesdayFeb 17, 2026 10:00 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company’s vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company’s profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform. To view the full press release, visit https://ibn.fm/iSd01 About Earth Science Tech, Inc. Earth Science Tech, Inc.…

TuesdayFeb 17, 2026 9:40 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Announces Governance and Capital Structure Initiatives to Advance Institutional Readiness

Earth Science Tech (OTC: ETST) announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. Building on approximately $3.3 million in net income for fiscal 2025 and anticipated $1.4 million in cost savings in fiscal 2026, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation, introduce advisory shareholder votes on executive compensation and Series B Preferred Stock retirement, rationalize its capital structure and reduce executive and board compensation, as management positions the company for disciplined growth and improved…

TuesdayFeb 17, 2026 9:40 am

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) to Launch Mudra Experience Studio Developer Platform

Wearable Devices (NASDAQ: WLDS) announced the upcoming launch of Mudra Experience Studio, a developer platform designed to standardize neural gesture input across extended reality, mobile and AI-powered applications. The platform will offer production-ready SDKs, a unified gesture taxonomy and OEM integration tiers to enable cross-platform deployment without platform-specific rebuilding, positioning the company to expand from a hardware-focused innovator to a full-stack platform provider, while supporting its 2026 rollout through a priority waitlist and recent leadership expansion within its ai6 Labs division. To view the full press release, visit https://ibn.fm/WHyvl About Wearable Devices Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a…

Site Search

Company Search

Category: QualityStocksNewsBreaks